anti-BCMA CAR-T cells / Hrain Biotech - LARVOL DELTA

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Hrain Biotechnology Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Enrollment closed • IO biomarker • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Hrain Biotechnology Co., Ltd.

New P2 trial • Hematological Malignancies • Multiple Myeloma • Oncology • CRP • IL10 • IL2 • TNFA

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects With R/R MM (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Hrain Biotechnology Co., Ltd.

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=10; Recruiting; Sponsor: Hrain Biotechnology Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature. (PubMed, Cancer Immunol Immunother) - "After a conditioning chemotherapy regimen of fludarabine and cyclophosphamide, patient took lenalidomide on day -1 and human-derived anti-BCMA CAR-T cells were infused on the next day. We demonstrated for the first time in patients that anti-BCMA CAR-T cell therapy combined with lenalidomide is feasible and effective in the treatment of RRMM. It provides a new strategy for RRMM patients who do not respond to anti-BCMA CAR-T cell therapy alone, and the adverse event is reversible."

Clinical • Journal • Bone Marrow Transplantation • Hematological Malignancies • Immune Modulation • Inflammation • Multiple Myeloma • Oncology • Transplantation